AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune reported positive interim data from a Phase 1 study of its oral NLRP3 inhibitor ACI-19764, demonstrating that the drug was safe and well-tolerated with a serum half-life greater than 30 hours. Preliminary results confirmed cerebrospinal fluid penetration and dose-dependent inhibition of IL-1beta release, with therapeutic doses expected to be 10mg or less once daily.
Key figures
- Drug Name
- ACI-19764
- Phase Of Trial
- Phase 1
- Ic50 n M
- 2-20.5
- Max dose mg
- 20
- Therapeutic dose mg
- ≤10mg once daily
- Serum half life hours
- > 30
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.